A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer

Authors: Yan, Tristan1; Black, Deborah2; Sugarbaker, Paul3; Zhu, Jacqui4; Yonemura, Yutaka5; Petrou, George6; Morris, David6

Source: Annals of Surgical Oncology, Volume 14, Number 10, October 2007 , pp. 2702-2713(12)

Publisher: Springer

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer.

Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. After independent quality assessment and data extraction, data were pooled for meta-analysis.

Thirteen reports of randomized controlled trials (RCTs) were included for quality appraisal and data extraction. Ten reports were judged to be of fair quality and subjected to meta-analysis. A significant improvement in survival was associated with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) alone (hazard ratio [HR] = 0.60; 95% CI = 0.43 to 0.83; p = 0.002) or HIIC combined with early postoperative intraperitoneal chemotherapy (EPIC) (HR = 0.45; 95% CI = 0.29 to 0.68; p = 0.0002). There was a trend towards survival improvement with normothermic intraoperative intraperitoneal chemotherapy (p = 0.06), but this was not significant with either EPIC alone or delayed postoperative intraperitoneal chemotherapy. Intraperitoneal chemotherapy was also found to be associated with higher risks of intra-abdominal abscess (RR = 2.37; 95% CI = 1.32 to 4.26; p = 0.003) and neutropenia (RR = 4.33; 95% CI = 1.49 to 12.61; p = 0.007).

The present meta-analysis indicates that HIIC with or without EPIC after resection of advanced gastric primary cancer is associated with improved overall survival. However, increased risk of intra-abdominal abscess and neutropenia are also demonstrated.

Keywords: Gastric carcinoma; Intraperitoneal chemotherapy

Document Type: Research article

DOI: 10.1245/s10434-007-9487-4

Affiliations: 1: Department of Surgery, University of New South Wales, St George Hospital, Sydney, NSW, Australia, Email: Tristan.Yan@unsw.edu.au 2: School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia 3: Department of Surgical Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA 4: School of Medicine, University of New South Wales, Sydney, NSW, Australia 5: Department of Gastric Cancer, Shizuoka Cancer Center, Shizuoka, Japan 6: Department of Surgery, University of New South Wales, St George Hospital, Sydney, NSW, Australia

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A